- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Likelihood of Approval Analysis for Lipid Storage Disorders (Lipidoses) Likelihood of Approval Analysis for Lipid Storage Disorders (Lipidoses)
$1,000 | March 2024 Overview How likely is it that the drugs in Lipid Storage Disorders (Lipidoses) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lipid Storage Disorders (Lipidoses) Overview Lipid storage disorders, or lipidoses,...
-
Product Insights
Product Insights Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023 Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Lipid Storage Disorders (Lipidoses) - Drugs In Development, 2023’, provides an overview of the Lipid Storage Disorders (Lipidoses) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lipid Storage Disorders (Lipidoses), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Gaucher Disease – Drugs In Development, 2023 Gaucher Disease – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease - Drugs In Development, 2023’, provides an overview of the Gaucher Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Fabry Disease – Drugs In Development, 2023 Fabry Disease – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Fabry Disease - Drugs In Development, 2023’, provides an overview of the Fabry Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2023 GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) - Drugs In Development, 2023’, provides an overview of the GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Product Insights Gaucher Disease Type I – Drugs In Development, 2023 Gaucher Disease Type I – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease Type I - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Gaucher Disease Type III – Drugs In Development, 2023 Gaucher Disease Type III – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease Type III - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type III pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type III, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
Sector Analysis Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
$6,995 | December 2023 Gaucher Disease Market Report Overview The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The major driver for this growth will be improved diagnostic approaches, the launch of Sanofi’s SRT venglustat malate, as well as the introduction of eliglustat tartrate generics. The Gaucher Disease market research report offers an...
-
Product Insights
Product Insights Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
$2,500 | September 2023 Gaucher Disease Clinical Trials Report Overview The Gaucher disease clinical trials report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Gaucher disease are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       Middle East...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.